Targeting HIV reverse transcriptase in novel ways.
Wainberg
M A
MA
McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada.
Gu
Z
Z
D000998:Antiviral Agents / Q000494:pharmacology; D004259:DNA-Directed DNA Polymerase / Q000276:immunology; D015224:Dideoxynucleosides / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D015316:Genetic Therapy; D006678:HIV / Q000201:enzymology* / Q000276:immunology; D015483:HIV Antibodies / Q000235:genetics* / Q000276:immunology; D015658:HIV Infections / Q000628:therapy*; D054303:HIV Reverse Transcriptase; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000235:genetics* / Q000276:immunology; D019384:Nucleic Acid Synthesis Inhibitors; D012194:RNA-Directed DNA Polymerase / Q000235:genetics / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D016914:Ribonuclease H / Q000037:antagonists & inhibitors / Q000276:immunology; D014162:Transfection
D000998:Antiviral Agents; D015224:Dideoxynucleosides; D015483:HIV Antibodies; D007140:Immunoglobulin Fab Fragments; D019384:Nucleic Acid Synthesis Inhibitors; D011993:Recombinant Fusion Proteins; C072416:reverse transcriptase, Human immunodeficiency virus 2; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase; D004259:DNA-Directed DNA Polymerase; D016914:Ribonuclease H